Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $-8,300,000
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 650
- Avg volume
- 36,054
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- 12%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- —
Company profile
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
- Phone
- 650 407 2376
- Website
- https://www.cero.bio
- Address
- 201 Haskins Way, Suite 230, South San Francisco, United States
Latest news
No headlines yet.
